Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage-Reference-Cited by-同舟云学术

Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage

Published:2023-07 Issue: Volume:177 Page:74-80
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Chun Brian,He Meiqi,Jones Cameron,Vasan Robin,Gabriel Nico,Jacobs Bruce L.,Hernandez Inmaculada,Davies Benjamin J.

Publisher

Elsevier BV

Subject

Urology

Reference21 articles.

1. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline;Chang;J Urol,2016

2. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group;Brausi;J Urol,2011

3. Bacillus Calmette-Guérin (BCG) therapy for bladder cancer: an update;Guallar-Garrido;ImmunoTargets Ther,2020

4. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis;Chou;J Urol,2017

5. Manufacturing and the market: rationalizing the shortage of Bacillus Calmette-Guérin;Bandari;Eur Urol Focus,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishing an Intravesical Doublet Chemotherapy Clinic for Nonmuscle-Invasive Bladder Cancer Patients;Urology Practice;2024-07

2. Editorial Comment;Journal of Urology;2024-07

3. US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guérin–Unresponsive and Bacillus Calmette-Guérin–Exposed Nonmuscle-Invasive Bladder Cancer;Urology Practice;2024-01